Parenteral nutrition (PN), containing fat emulsions derived from soybean, has been implicated in the progression of PN-associated liver disease and cholestasis, particularly in infants with short bowel syndrome. Clinical use of Omegaven, a parenteral fish-oil emulsion, has been shown in recent studies to be a promising therapy to reverse liver disease and cholestasis. This review summarizes the rationale, relevant clinical investigations and future direction of Omegaven therapy for PN-dependent infants.
Introduction
Short bowel syndrome (SBS) and intestinal failure are chronic diseases with high morbidity and mortality. It is estimated that the overall incidence of SBS among all neonatal intensive care units is 22.1 per 1000 admissions and 24.5 per 100 000 live births, with an all-case fatality rate of 37.5%. 1, 2 Children affected with SBS are often dependent on parenteral nutrition (PN) for survival. The majority of health complications and deaths among SBS patients occur from infection and hepatobiliary dysfunction due to prolonged PN-associated liver disease (PNALD), with premature infants and low birth weight babies representing a particularly at-risk subgroup. [3] [4] [5] [6] The pathophysiology of PNALD is unknown, although various molecular theories have been proposed. 7, 8 Amino-acid deficiencies and excesses, trace elements and fat emulsions have been implicated in the development of PNALD. Recent investigations have more precisely linked phytosterols as the primary offending agent in PN. [9] [10] [11] The objective of this review is to summarize the use of Omegaven (Fresenius-Kabi, Bad Homburg, Germany) in treating PN-associated cholestasis (PNAC) and PNALD in infants. Omegaven is a 10% fish-oil emulsion developed specifically for parenteral use. A literature search was conducted through MEDLINE using keywords Omegaven, omega-3, lipid emulsion, fish oil, parenteral nutrition-associated liver disease and parenteral nutritionassociated cholestasis. Articles were included based on the relevance of the investigations to the objective of this review.
Rationale for omega-3 fatty acids in parenteral nutrition A comparison summary between typical fat emulsions and Omegaven is shown in Table 1 . As illustrated, unlike the typical fat emulsions derived from soybean or safflower oil comprised of o-6 fatty acids (FA), Omegaven contains only o-3 polyunsaturated FA. The rationale for using fish oil in fat emulsions may be because of the interference of the arachidonic acid inflammatory pathway by o-3 FA compared with the pro-inflammatory nature and induced immunological dysfunction of o-6 FA. 12 Grimmiger et al.
13
showed that eicosapentaenoic acid, a type of o-3 FA, induced less vascular leakage of inflammatory leukotrienes in vitro than arachidonic acid, a type of o-6 FA. The exact hepatoprotective mechanism of o-3 FA is not entirely known, but it is theorized that o-3 FAs help to regulate the tumor necrosis factor-a responsible for damaging cellular lipopolysaccharides, typically seen in sepsis.
Lipid hydroperoxides are present in high levels in intravenous fat solutions, with histological evidence of peroxidation of cell membranes seen in neonates with cholestasis.
14 Currently, in the United States, the only two fat emulsions available are made from soybean oil. Phytosterols, present in soy-derived lipids, have been implicated in the pathogenesis of hepatotoxicity. 15 It has been shown that delayed hepatic clearance with steatosis occurs with the use of soybean-based emulsions. 16 In particular, phytosterols may have a deleterious effect on biliary secretion. Carter et al. 17 demonstrated that phytosterols may function as a bile acid nuclear receptor antagonist, slowing bile acid transport through the liver. In contrast, fish oil does not contain any phytosterols. Van Aerde et al. 18 and Alwayn et al. 19 showed through pig and murine models, respectively, that parenteral fish oil does not impair biliary secretion and may prevent steatosis.
The advent of Omegaven
Cavicchi et al. 20 showed, through a prospective investigation of 90 adults on PN, that PNALD and liver failure were significantly associated with the lipid concentration and duration of PN use. PNALD was present in 26 ± 9% at 2 years and in 50 ± 13% at 6 years. The investigators also determined through multivariate analysis that o-6 FA lipid emulsion of greater than 1 g/kg of body weight per day was a significant predictor for developing PNALD. A retrospective analysis by Colomb et al.,
11 on 10 children receiving long-term PN with lipids, illustrated that decreasing the concentration of lipid emulsion improved PNAC. Among the 10 children, 17 of their 23 total episodes of cholestasis resolved with decreasing or discontinuing lipids.
The results of a prospective, multicenter trial (n ¼ 661 adults) from Germany were recently published showing the potential benefits of Omegaven in reducing infections and improving postoperative health outcomes in the critically ill population. 21 In the United States, the first pediatric use of Omegaven was on a 17-year-old bone marrow transplant patient with severe soy allergy who developed essential FA deficiency on fat-free PN at Children's Hospital Boston. 22 Parenteral fish oil was later shown to be sufficient as monotherapy to prevent essential FA deficiency in premature infants. 23 The same group in Boston, Gura et al., 24 reported that two infants with intestinal failure and PNALD had significant improvement of hepatic function and complete resolution of cholestasis on Omegaven administration. This experience led to the first US trial of Omegaven in 18 infants with SBS and PNAC (serum direct bilirubin level >2 mg/dl) while receiving soybean emulsions. 25 The investigators found that, compared with historical controls, the Omegaven group had significantly improved reversal of cholestasis with a median time of reversal of 9.4 vs 44.1 weeksF4.8 times faster in the Omegaven cohort than in the historical cohort. When the analysis was adjusted for baseline bilirubin concentration, gestational age and the diagnosis of necrotizing enterocolitis, infants who received Omegaven had 6.8 times faster resolution of cholestasis than in infants who had received soybean emulsions.
A larger, more recent, open-labeled trial of Omegaven administered to cholestatic infants with SBS (n ¼ 42) had significantly better outcomes than the soybean oil emulsion group (n ¼ 49). 26 The Omegaven cohort had three deaths and one liver transplantation, whereas the soybean oil cohort had 12 deaths and six liver transplantations (P ¼ 0.005). A total of 19 of the 38 living, non-transplanted patients receiving Omegaven had reversal of PNAC compared with 2 of 36 patients receiving soybean oil emulsion. Cox regression models indicated that cholestasis was reversed six times faster (95% confidence interval: 2.0 to 37.3) in the Omegaven group than in the soybean oil group. Regression models also showed that Omegaven use was not associated with hypertriglyceridemia, coagulopathy or essential FA deficiency.
Smaller retrospective studies from Canada and Hong Kong support the findings from Boston. Diamond et al. 27 found that in 12 children with SBS and advanced PNALD (median age of 7.5 months, range 3.6 to 46 months) and on PN before Omegaven initiation (median time of 28.4 weeks, range 15.3 to 55.3 weeks), Omegaven restored liver function and achieved sustained resolution of cholestasis in 9 of the 12 patients with no adverse side effects. The remaining three patients developed progressive liver failure and cholestasis and ultimately received liver transplants. Similarly, Cheung et al. 28 observed that Omegaven halted progressive PNALD in three of four preterm infants with intestinal failure and PN-associated cholestasis. The fourth infant did not respond to parenteral fish oil because of sepsis and ongoing bowel inflammation.
Further, at Seattle Children's Hospital, 10 cholestatic infants with conjugated hyperbilirubinemia (average of 6.7Frange 3 to 17.3 mg/dl) with extreme intestinal failure, all totally dependent on total PN, were switched to Omegevan. Nine sustained normalization of the conjugated bilirubin. One had the conjugated bilirubin that decreased to 2.7 mg/dl and then rose to 13 mg/dl.
Although current evidence suggests efficacy of o-3 FA in the treatment and reversal of PNALD and PNAC, Soden et al. 29 reported that hepatic fibrosis persisted in two infants with intestinal failure on Omegaven, despite improvements of cholestasis. This observation may be related to the findings by Yang et al. 30 in a retrospective chart review of 31 children with PNALD. Among the patients achieving PN independence, only 50% of the patients normalized their serum alanine aminotransferase, despite 74% of them attaining normal direct bilirubin. The disparity between biochemical normalization of cholestasis and persistence of liver disease after cessation of PN could indicate that Omegaven may not be successful in healing advanced forms of liver disease.
Conclusion and future directions SBS and intestinal failure with PN dependency have serious, longterm health consequences. The potential for Omegaven to benefit patients with PNALD and PNAC is substantial. Education of pediatric subspecialists about the benefits of Omegaven is the first step in helping infants and children with PNALD due to SBS and intestinal failure. Use of Omegaven or any other similar product is not Food and Drug Administration approved and is still in the experimental stages in the United States. Health-care providers can obtain Omegaven for patients on an individual basis by following the directions outlined in Tables 2 and 3 . There are several limitations to the recent prospective investigations. Both preliminary trials of Omegaven from Boston used historical controls, which can introduce bias. 25, 26 Moreover, lipid loads for soybean oil was not constant across cohorts. A study design with standard randomization will be a key component in future controlled trials. As mentioned above, investigations are needed to directly correlate improvements in biochemical parameters of hepatic and biliary function with histology. It is unknown at what point in the progression of PNALD that Omegaven will cease to be a beneficial intervention. Finally, future studies should focus on defining the potential for prevention of cholestasis with Omegaven therapy, as current studies only suggest that parenteral fish oil may reverse PNAC.
One such study is currently in progress. At Boston Children's Hospital, a randomized trial is underway in infants with surgical gastrointestinal disease. Inclusion criteria include congenital or acquired gastrointestinal disease requiring surgical intervention (for example, midgut volvulus, gastrochisis (with known or suspected atresia(s), perforation(s), requiring a jejunostomy or bowel resections >20 cm), omphalocele, jejunal atresia or necrotizing enterocolitis (no peritoneal drains) or duodenal atresia); expected duration of PN for at least 21 days; and baseline Table 3 Steps to obtain Omegaven for patient use (http://www.oley.org/ documents/How_Physicians_Can_Obtain_Omegaven.pdf) How Physicians Can Obtain Omegaven (Revised 28 July 2009) Note: many of these steps will occur concurrently so the prescriber should start submitting and not wait for a response to proceed to the next step: 1. Obtain permission from Food and Drug Administration (FDA). E-mail the FDA to alert them that a request for Omegaven is forthcoming. Send them your contact information (including phone number) and brief information on the patient. It is not necessary to fax or send them any forms at this time. They will contact you and e-mail you the proper documents. All requests, questions, problems should go to the following e-mail address: cder-dgpeind@fda.hhs.gov. This is to ensure all requests/questions are answered in a timely manner. The FDA will be rotating staff to monitor this account daily. 2. Next you need to get a veterinary registration with the United States Department of Agriculture. Information on how to do this is posted at: http://www.aphis.usda.gov/ import_export/index.shtml 3. Submit a copy of the protocol you plan to follow to your Investigational Review Board. 4. Place an order for Omegaven with International Pharmacy in Hamburg, Germany. Using this pharmacy is much easier if you are only obtaining Omegaven for one patient; Fresenius-Kabi will not ship small orders. I am sure there are other international pharmacies that could also do this, and we are not endorsing this company, but this is the pharmacy we have dealt with in the past. If you use Pharmacy International, however, they will not accept US credit cards. The preferred method of payment for them would be an international bank transfer or wire transfer to the company's bank account. They will submit the bank details by e-mail directly to the customer. Checks are still a hassle as they might be lost, take weeks to be delivered, or be written for the wrong amount as the conversion rate has totally changed by the time they are received. Shipping is extra. Contact information for the company: http://www.pharmacy-international.de Export Sales Pharmacy International Hamburg (Germany) Phone: +49 40 241 241 Fax: +49 40 280 2518 Email: mail@pharmacy-international.de Once you place the order, they will e-mail you when it is in stock. Then you must call a courier to deliver it or have Pharmacy International ship it at an additional charge. Pharmacy International has several shipping options available. Any questions: Please contact: Kathleen Gura Kathleen.Gura@childrens.harvard.edu Mark Puder Mark.Puder@childrens.harvard.edu direct bilirubin <1.0 mg/dl (normal). A key exclusion criteria is exposure to soybean oil-fat emulsion for greater than 3 weeks (>21 days) at time of enrollment. The infants will be randomized to equal doses of Intralipid or Omegevan. Patients and families and the medical care team will be blinded to the treatment group allocation. The Boston study results are awaited with much anticipation. The readers should keep their eyes on a number of other studies cited at http://clinicaltrials.gov 31 that are evaluating safety and efficacy of Omegevan in treating PN-associated liver disease.
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